High prevalence and molecular characterization of extended-spectrum β-lactamase-producing Proteus mirabilis strains in southern Croatia

References

1. Arlet G., Brami G., Décrè D., Flippo A., Gaillot O., Lagrange P. H., Philippon A. 1995; Molecular characterisation by PCR-restriction fragment length polymorphism of TEM β -lactamases. FEMS Microbiol Lett 134:203–208
   [Google Scholar]
2. Biendo M., Thomas D., Laurans G., Hamdad-Daoudi F., Canarelli B., Rousseau F., Castelain S., Eb F. 2005; Molecular diversity of Proteus mirabilis isolates producing extended-spectrum β -lactamases in a French university hospital. Clin Microbiol Infect 11:395–401 [CrossRef]
   [Google Scholar]
3. Bonnet R., De Champs C., Sirot D., Chanal C., Labia R., Sirot J. 1999; Diversity of TEM mutants in Proteus mirabilis . Antimicrob Agents Chemother 43:2671–2677
   [Google Scholar]
4. Bradford P. A. 2001; Extended spectrum β -lactamases. Clin Microbiol Rev 14:933–951 [CrossRef]
   [Google Scholar]
5. Canton R., Coque T. M. 2006; The CTX-M β -lactamase pandemic. Curr Opin Microbiol 9:466–475 [CrossRef]
   [Google Scholar]
6. CDC 2004; One-day (24–28 h) standardized laboratory protocol for molecular subtyping of Escherichia coli O157 : H7, non-typhoidal Salmonella serotypes, and Shigella sonnei by pulsed field gel electrophoresis. Atlanta: Centers for Disease Control and Prevention http://www.cdc.gov/pulsenet/protocols.htm
7. CLSI 2008a; Performance Standards for Antimicrobial Disk Susceptibility Tests ; Approved Standard. , 10th edn.M02–A10 Wayne, PA: Clinical and Laboratory Standards Institute;
8. CLSI 2008b; Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically ; Approved Standard. , 8th edn.M07–A8 Wayne, PA: Clinical and Laboratory Standards Institute;
9. Coker C., Poore C. A., Li X., Mobely H. L. 2000; Pathogenesis of Proteus mirabilis urinary tract infection. Microbes Infect 2:1497–1505 [CrossRef]
   [Google Scholar]
10. Empel J., Baraniak A., Literacka E., Mrówka A., Fiett J., Sadowy E., Hryniewicz W., Gniadkowski M. the Beta-PL Study Group 2008; Molecular survey of β -lactamases conferring resistance to newer β -lactams in Enterobacteriaceae isolates from Polish hospitals. Antimicrob Agents Chemother 52:2449–2454 [CrossRef]
    [Google Scholar]
11. Fiett J., Palucha A., Miaczynska B., Stankiewicz M., Przondo-Mordarska H., Hryniewicz W., Gniadkowski M. 2000; A novel complex mutant β -lactamase, TEM-68, identified in a Klebsiella pneumoniae isolate from an outbreak of extended-spectrum β -lactamase-producing Klebsiellae . Antimicrob Agents Chemother 44:1499–1505 [CrossRef]
    [Google Scholar]
12. Ho P. L., Chow K. H., Yuen K. Y., Ng W. S., Chau P. Y. 1998; Comparison of a novel, inhibitor-potentiated disc-diffusion test with other methods for the detection of extended-spectrum β -lactamases in Escherichia coli and Klebsiella pneumoniae . J Antimicrob Chemother 42:49–54 [CrossRef]
    [Google Scholar]
13. Jarlier V., Nicolas M. H., Fournier G., Philippon A. 1988; Extended broad-spectrum β -lactamases conferring transferable resistance to newer β -lactam agents in Enterobacteriaceae : hospital prevalence and susceptibility patterns. Rev Infect Dis 10:867–878 [CrossRef]
    [Google Scholar]
14. Jean S. S., Hsueh P. R., Lee W. S., Chang H. T., Chou M. Y., Chen I. S., Wang J. H., Lin C. F., Shyr J. M. other authors 2009; Nationwide surveillance of antimicrobial resistance among Enterobacteriaceae in intensive care units in Taiwan. Eur J Clin Microbiol Infect Dis 28:215–220 [CrossRef]
    [Google Scholar]
15. Lau S. H., Kaufmann M. E., Livermore D. M., Woodford N., Willshaw G. A., Cheasty T., Stamper K., Reddy S., Cheesbrough J. other authors 2008; UK epidemic Escherichia coli strains A–E, with CTX-M-15 β -lactamase, all belong to the international O25 : H4-ST131 clone. J Antimicrob Chemother 62:1241–1244 [CrossRef]
    [Google Scholar]
16. Livermore D. M. 1998; β -Lactamase-mediated resistance and opportunities for its control. J Antimicrob Chemother 41:25–41
    [Google Scholar]
17. Nijssen S., Florijn A., Bonten M. J., Schmitz F. J., Verhoef J., Fluit A. C. 2004; Beta-lactam susceptibilities and prevalence of ESBL-producing isolates among more than 5000 European Enterobacteriaceae isolates. Int J Antimicrob Agents 24:585–591 [CrossRef]
    [Google Scholar]
18. Nüesch-Inderbinen M. T., Hächler H., Kayser F. H. 1996; Detection of genes coding for extended-spectrum SHV β -lactamases in clinical isolates by a molecular genetic method, and comparison with E test. Eur J Clin Microbiol Infect Dis 15:398–402 [CrossRef]
    [Google Scholar]
19. Pitout J. D., Wei Y., Church D. L., Gregson D. B. 2008; Surveillance for plasmid-mediated quinolone resistance determinants in Enterobacteriaceae within the Calgary Health Region, Canada: the emergence of aac(6′)-Ib-cr . J Antimicrob Chemother 61:999–1002 [CrossRef]
    [Google Scholar]
20. Poyart C., Mugnier P., Quesne G., Berche P., Trieu-Cuot P. 1998; A novel extended-spectrum TEM-type β -lactamase (TEM-52) associated with decreased susceptibility to moxalactam in Klebsiella pneumoniae . Antimicrob Agents Chemother 42:108–113
    [Google Scholar]
21. Sardelic S., Bedenic B., Colinon C., Sijak D., Kalenic S. 2009; First report of TEM-52 lactamase in Proteus mirabilis strains from Croatia. Clin Microbiol Infect 15:1204
    [Google Scholar]
22. Spanu T., Luzzaro F., Perilli M., Amicosante G., Toniolo A., Fadda G. the Italian ESBL Study Group 2002; Occurrence of extended-spectrum β -lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to β -lactams and other antimicrobial drugs. Antimicrob Agents Chemother 46:196–202 [CrossRef]
    [Google Scholar]
23. Tonkic M., Goic-Barisic I., Punda-Polic V. 2005; Prevalence and antimicrobial resistance of extended-spectrum β -lactamases-producing Escherichia coli and Klebsiella pneumoniae strains isolated in a university hospital in Split, Croatia. Int Microbiol 8:119–124
    [Google Scholar]
24. Tonkić M., Goić-Barišić I., Novak A., Karanović J., Šiško-Kraljević K., Mohar B., Punda-Polić V. 2008; Prevalence and antibiotic resistance of extended-spectrum β -lactamases (ESBLs)-producing Proteus mirabilis strains at University Hospital Split. In Abstracts Book of the 8th Croatian Congress of Clinical Microbiology with International Participation Zagreb: 25–28 May 2008 pp 43–45 Edited by Kalenić S. Zagreb: Croatian Society of Medical Microbiology and Parasitology;
    [Google Scholar]
25. Winokur P. L., Canton R., Casellas J. M., Legakis N. 2001; Variation in the prevalence of strains expressing an extended-spectrum β -lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin Infect Dis 32:S94–S103 [CrossRef]
    [Google Scholar]
26. Woodford N., Ward M. E., Kaufmann M. E., Turton J., Fagan E. J., James D., Johnson A. P., Pike R., Warner M. other authors 2004; Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum β -lactamases in the UK. J Antimicrob Chemother 54:735–743 [CrossRef]
    [Google Scholar]
27. Woodford N., Fagan E. J., Ellington M. J. 2005; Multiplex PCR for rapid detection of genes encoding CTX-M extended-spectrum β -lactamases. J Antimicrob Chemother 57:154–155 [CrossRef]
    [Google Scholar]
28. Zong Z., Partridge S. R., Thomas L., Iredell J. R. 2008; Dominance of bla _CTX-M within an Australian extended-spectrum β -lactamase gene pool. Antimicrob Agents Chemother 52:4198–4202 [CrossRef]
    [Google Scholar]